Nektar wins $90M jury verdict against Eli Lilly in rezpegaldesleukin license dispute

NEKTAR THERAPEUTICS

Jury found Lilly breached the implied covenant of good faith and fair dealing in the rezpegaldesleukin license deal; verdict returned Sept 24, 2026 (N.D. Cal. 3:23-cv-03943-JD).
Jury awarded Nektar $90 million in damages plus interest, with the interest amount to be determined by the District Court.
Nektar filed the complaint in August 2023 alleging breach of contract and breach of implied covenant; jury trial began September 8, 2026.
Verdict remains subject to post-trial proceedings and any resulting judgment may be subject to appeal.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.